Biomea Fusion, Inc. ( BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes March 30, 2026 3:00 PM EDT Michael J. Hitchcock - Interim CEO & Director Ramses Erdtmann - ...
Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety ...
There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results